Stock GNPX GENPREX, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Genprex, Inc.

Equities

GNPX

US3724462037

Market Closed - Nasdaq
Other stock markets
 21:30:01 02/05/2024 BST 		5-day change 1st Jan Change
2.36 USD +4.42% Intraday chart for Genprex, Inc. +11.32% -74.35%
04-03 Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa Therapy in Combination with Tecentriq to Treat Small Cell Lung Cancer CI
04-02 Genprex, Inc. Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex® Delivery System CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting
AQ
Genprex Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex Delivery System
AQ
Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa Therapy in Combination with Tecentriq to Treat Small Cell Lung Cancer
CI
Genprex, Inc. Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex® Delivery System
CI
Genprex, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
HC Wainwright Initiates Genprex With Buy Rating, $10 Price Target
MT
Genprex Closes $6.5 Million Registered Direct Offering of Shares, Accompanying Warrants
MT
Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
AQ
Genprex Launches $6.5 Million Securities Offering; Shares Fall
MT
Genprex Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat Cancers
AQ
Genprex Awarded South Korean Patent for Drug Candidate Reqorsa Plus Antibodies to Treat Cancers
MT
Genprex, Inc. Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat Cancers
CI
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting
AQ
Genprex Expands Nonclinical Programs into New Therapeutic Indications with Research Collaborators
AQ
Genprex, Inc. Expands Nonclinical Programs into New Therapeutic Indications with Research Collaborators
CI
Genprex to Present at Upcoming BIO CEO and Investor Conference
AQ
Genprex, Inc. Announces First Patient Dosed in Phase 2a Expansion of Acclaim-1 Clinical Study of Reqorsa Therapy in Combination with Tagrisso to Treat Non-Small Cell Lung Cancer
CI
Genprex, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
North American Morning Briefing : Investors Weigh -2-
DJ
Genprex to Present at BIO-Europe 2023 Conference
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. GNPX Stock
  4. News Genprex, Inc.